Rationale and design of the Japanese Heart Failure Outpatients Disease Management and Cardiac Evaluation (J-HOMECARE)  by Tsuchihashi-Makaya, Miyuki et al.
Journal of Cardiology (2011) 58, 165—172
avai lab le at www.sc iencedi rec t .com
journa l homepage: www.e lsev ier .com/ locate / j j cc
Original article
Rationale and design of the Japanese Heart Failure
Outpatients Disease Management and Cardiac
Evaluation (J-HOMECARE)
Miyuki Tsuchihashi-Makaya (PhD)a,∗, Hisashi Matsuo (MD, PhD)b,
Shigeo Kakinoki (MD, PhD)c, Shigeru Takechi (MD, PhD)d,
Hiroyuki Tsutsui (MD, PhD, FJCC)a, for the J-HOMECARE Investigators1
a Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan
b Department of Cardiology, Keiwakai Ebetsu Hospital, Ebetsu, Japan
c Department of Cardiology, Otaru Kyokai Hospital, Otaru, Japan
d Department of Cardiology, Date Red Cross Hospital, Date, Japan
Received 12 April 2011; received in revised form 18 April 2011; accepted 21 April 2011
KEYWORDS
Heart failure;
Disease management;
Psychological status;
Prognosis;
Quality of life
Summary
Background: Although many studies have demonstrated the efﬁcacy of disease management
programs on mortality, morbidity, quality of life (QOL), and medical cost in patients with heart
failure (HF), no study has focused on psychological status as an outcome of diseasemanagement.
In addition, very little information is available on the effectiveness of disease management
programs in other areas than the USA and Europe.
Methods: The Japanese Heart Failure Outpatients Disease Management and Cardiac Evaluation
(J-HOMECARE) is a randomized controlled trial in which 156 patients hospitalized with HF will be
randomized into usual care or a home-based disease management arm receiving comprehensive
advice and counseling by visiting nurses during the initial 2 months and telephone follow-up for
the following 4 months after discharge. This study evaluates depression and anxiety (Hospital
Anxiety and Depression Scale), mortality, readmission due to HF, and QOL (Short Form-8). Data
are collected during index hospitalization and then 2, 6, and 12 months after discharge. This
study started in December 2007, and the ﬁnal results are expected in 2011.
E wiConclusion: The J-HOMECAR
agement for psychological statu
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ntroduction
eart failure (HF) is one of the leading causes of death and
ospitalization in developed countries. It is often associated
ith multiple co-morbidities and complications, as well as
mpaired quality of life (QOL). Although many therapeutic
ptions have reduced mortality and morbidity in patients
ith HF [1—4], frequent re-hospitalization due to worsening
F, low QOL [5], and psychological problems remain a crit-
cal issue [6]. Our previous studies demonstrated that poor
ollow-up as well as psychosocial distress such as anxiety
as an independent predictor associated with hospitaliza-
ion due to worsening HF [7,8].
To improve outcomes of HF patients, a variety of disease
anagement programs have been developed and tested
ver the past 25 years [9—11]. These programs include HF
linics, home-based intervention, and tele-monitoring. The
ey components of all of these interventions were edu-
ation and counseling, symptom monitoring by a nurse,
ccessibility of healthcare provider in case of problems,
ptimization of medication, and social support service after
ischarge. They have been reported to decrease rehos-
italization due to worsening HF, increase time to ﬁrst
ajor event, decrease medical costs, and improve QOL [12].
owever, some studies have failed to support these posi-
ive ﬁndings, by reporting negative or inconclusive results
13,14]. In addition, the differences in national healthcare
ystems raise questions about the suitability and compara-
ility of these programs in different countries. To the best
f our knowledge, no trials have been conducted to eval-
ate the effect of disease management programs in other
ountries other than the USA, Europe, and Australia. More-
ver, almost all previous studies have evaluated the effects
f disease management on mortality, readmission due to HF,
OL, and medical costs. Even though psychosocial distress,
ncluding depression and anxiety, is common among patients
ith HF and is a high risk for mortality and morbidity in
F [8,15], there is no trial to assess the efﬁcacy of dis-
ase management programs for the psychosocial status of HF
atients.
The Japanese Heart Failure Outpatients Disease Manage-
ent and Cardiac Evaluation (J-HOMECARE) is a randomized
ontrolled trial to evaluate the efﬁcacy of home-based dis-
ase management programs compared with usual care in
mproving psychosocial status, mortality, HF hospitalization,
nd QOL in Japanese HF patients.
tudy design
verview
-HOMECARE is a multicenter, randomized, efﬁcacy trial
esigned to evaluate the efﬁcacy of home-based disease
anagement programs on psychosocial status and QOL as
ell as mortality and morbidity as compared to usual care in
apanese HF patients. This study has been approved by the
thics Committee of Hokkaido University Graduate School
f Medicine. Recruited patients with HF were randomized
nto usual care and home-based disease management groups
etween December 2007 and March 2010. Patients undergo
heir respective J-HOMECARE treatment for 6 months and
h
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re then followed up for an additional 6 months. All data
ollection was scheduled to end in March 2011.
tudy objectives
he primary objective of J-HOMECARE is to determine the
ffectiveness of interventions, as compared to that of usual
are, on psychological status, including depression and anx-
ety, in HF patients. The secondary objective is to determine
he effectiveness of interventions, compared to that of usual
are, on all-cause death, cardiac death, sudden cardiac
eath, readmission due to decompensated HF, and QOL.
tudy patients and baseline assessment
he process of the trial is shown in Fig. 1. All study candi-
ates are required to have had a hospital admission for HF
ith symptoms and signs of HF and a pre-existing history
f chronic HF [New York Heart Association (NYHA) II—IV].
ligible patients must be at least 18 years of age. Reasons
or exclusion from the study are as follows: end-stage HF
eﬁned as requiring mechanical support or continuous intra-
enous inotropic support; a serious life-threatening illness
ith a life-expectancy of <6 months; stroke within the last
months; cognitive dysfunction; substance abuse or psy-
hotic disorder; patients whose physician or nurses refused
ccess.
After informed consent has been obtained from eligible
atients, they are randomized on a 1:1 basis, to either usual
are or a home-based disease management program.
Baseline and all annual examinations consist of: (1) clin-
cal characteristics including height, body weight, pulse,
nd blood pressure; (2) etiology of HF; (3) risk fac-
ors such as hypertension, diabetes mellitus, dyslipidemia,
moking habits, and/or alcohol drinking habits; (4) comor-
idities such as prior myocardial infarction (MI), atrial
brillation, ventricular arrhythmias, hyperuricemia, chronic
idney disease, anemia, stroke, chronic obstructive pul-
onary disease, locomotor disability, prior percutaneous
oronary intervention (PCI) or coronary artery bypass graft
CABG); (5) severity of HF [NYHA functional class, brain
atriuretic peptide (BNP)], and echocardiography; (6) treat-
ent at hospital discharge; and (7) a questionnaire assessing
epression, anxiety, QOL, and physical activity (Table 1).
ntervention protocol
nrolled patients receive comprehensive discharge educa-
ion using a booklet provided by a cardiologist, nurse, dieti-
ian, or pharmacist. This booklet provides knowledge and
nformation on pathophysiology, medical treatment, diet,
hysical activity, lifestyle modiﬁcation, self-measurement
f body weight, self-monitoring of worsening HF, and emer-
ency contact methods (Fig. 2). Follow-up assessments were
erformed 1, 2, 6, and 12 months after discharge.
A home-based disease management program consists ofome visit by nurse to provide symptom monitoring, edu-
ation, and counseling and telephone follow-up by nurse
n addition to routine follow-up by cardiologist (Table 2).
home visit is made within 14 days after discharge from
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Patient identification
Patients hospitalized for HF with signs and symptoms of fluid overload 
and a pre-existing history of chronic HF (NYHA II-IV)
Eligibility Screening
Inclusion criteria
1.Age ≥ 18 years
Exclusion criteria
1.End-stage HF defined as requiring mechanical support 
or continues intravenous inotropic support
2.A serious life-threatening illness with a life-expectancy of <6 months
3.Stroke within the past 3 months
4.Cognitive dysfunction 
5.Substance abuse or psychotic disorder
Informed consent
6.Managed by visiting nursing
7.Long distance between patients’ home and hospital
Baseline assessment
Randomization
-Clinical characteristics, etiology of HF, risk factor, comorbidity, severity, treatment 
-Assessment of depression, anxiety, QOL, and physical activity using by questionnaire
Comprehensive discharge education
Structured education and counseling using booklet and materials 
by cardiologist, nurse, dietitian, and pharmacist.
Usual care group Home-based disease management group
Routine follow-up by cardiologist 
or primary care physician 
1. Home visit by nurse
Telephone follow-up by nurse2.
Routine follow-up by cardiologist3.
Outcome assessments: 2, 6, and 12 months after discharge
Psychological status (depression and anxiety)1.
Mortality (all-cause death, cardiac death, and sudden cardiac death)2.
Readmission due to HF3.
QOL4.
ure;
uFigure 1 Study protocol of J-HOMECARE. HF, heart fail
the hospital. The nurse visits the patient’s home to assess
how the patient is coping in the home environment, HF
status, general health status, adherence to medication,
lifestyle modiﬁcation, daily activity, and social support
needs (Table 3). Home visits are made once per two weeks
v
m
i
n
Table 1 Questionnaires used in the J-HOMECARE study.
Assessment schedule
Depression Baseline, 1, 3, 6, and 12 mont
Anxiety Baseline, 1, 3, 6, and 12 mont
Quality of life Baseline, 1, 3, 6, and 12 mont
Physical activity Baseline, 1, 3, 6, and 12 montNYHA, New York Heart Association; QOL, quality of life.
ntil 2 months after discharge. After the conclusion of home
isiting, the nurse conducts telephone follow-up once a
onth until 6 months after discharge (Fig. 3). Nurses mon-
tor HF symptoms, patient’s general health status, and the
eed of other health and social support (Table 4). The
Questionnaire
hs Hospital Anxiety and Depression Scale
hs Hospital Anxiety and Depression Scale
hs Medical outcome study Short Form-8
hs Speciﬁc activity scale
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Table 2 Components and contents of the home-based disease management program during home visits.
Components Contents
Coping in the home environment Advice on how to adapt patients’ current lifestyle to accommodate recommended changes
Assessment and support of mismatch between physical disability and home environment
HF status Assessment of HF-related symptoms, daily weight, and vital signs
Consultation with cardiologist, if needed
General health status Assessment of comorbidity, psychosocial response, and activity of daily living
Consultation with cardiologist or other health professional, if needed
Adherence to medication Assessment of coping with regimen
Advice on effective coping strategy
Assessment of side effects
Support to caregiver’s optimal monitoring for patient’s adherence
Consultation with pharmacist or cardiologist, if needed
Lifestyle modiﬁcation Advice on sodium restriction, ﬂuid restriction, alcohol restriction, and smoking cessation
Consultation with dietician or cardiologist
Daily activity Assessment of work, daily, and leisure activity
Social support needs Assessment of inadequate social support and social isolation
Consultation with social worke
HF, heart failure.
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aigure 2 Photos of patient education booklet. (A) Booklet and
heck list of body weight. (B) A page of the booklet.
urse consults a multidisciplinary team during the interven-
ion period to optimize her advice for each patient. This
ultidisciplinary team consists of a cardiologist, dietician,
harmacist, and social worker. Other healthcare profession-
ls are consulted, as required.
c
a
b
or, if needed
Patients in the control group receive usual care and
ollow-up. After hospital discharge, patients assigned to the
sual care group continue to receive routine management by
he cardiologist. No extra follow-up by a HF nurse or multi-
isciplinary team is provided. Patients are treated according
o the current guidelines for HF management by standard
edications.
ndpoints
he primary end point is the change in psychological status
ncluding depression and anxiety. We assess the change in
he prevalence of depression and anxiety and the change
n the score of the Hospital Anxiety and Depression Scale
HADS) from baseline to 12 months after discharge [16]. A
hange in the QOL score is assessed by the Short Form-8.
atients’ QOL, psychological status, and physical activity are
ssessed in the outpatient clinic or by mail at 2, 6, and 12
onths after discharge (Table 1).
The secondary endpoint is the time to the ﬁrst event
all-cause death, cardiac death, sudden cardiac death, or
ospitalization for HF). Hospitalization for HF is deﬁned as
n unplanned overnight stay in a hospital (different dates
or admission and discharge) due to progression of HF or
irectly related to HF. Data are collected by chart reviews
r interview to the patient.
tatistical analysis and sample size
ll analyses are conducted according to the intention-to-
reat principle. Data from all randomized patients will be
nalyzed according to the treatment assignment. Baseline
haracteristics will be compared between the 2 treatment
rms to assess covariate balance, and any imbalances will
e adjusted in multivariate models. To meet the primary
bjective of the study, the primary endpoint, the change
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Table 3 Check list of patient status during home visit.
Vital Sign Blood pressure / mmHg
Heart rate /min
Breaths per minute /min
Heart failure symptoms Dyspnea/Shortness of breath Yes/No
Paroxysmal nocturnal dyspnea Yes/No
Orthopnea Yes/No
Cough/Sputum Yes/No
Fatigue Yes/No
Oliguria/Nocturia Yes/No
Coldness of limbs Yes/No
Palpitation Yes/No
Edema Yes/No
Anorexia Yes/No
Insomnia Yes/No
Body weight Self-measurement of body weight Yes/No*
Body weight /kg
Body weight change from baseline /kg
Life style modiﬁcation Adherence to sodium or ﬂuid restriction Yes/No*
Excessive activity Yes/No*
Physical or mental stress Yes/No*
Infection prevention Yes/No*
Alcohol restriction Yes/No*
Smoking cessation Yes/No*
Adherence to medical regimen Poor Yes*/No
If yes, name and number of missed drugs
Social support Need for additional specialized care Yes*/No
Need for other social resources Yes*/No
Report to primary physician Need for additional education or support Yes*/No
Appointment of next clinic visit Yes/No
edia
/care
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aNeed for imm
* Require additional education or support for patient or families
in psychological status between baseline to 12 months
after discharge, will be evaluated using the paired t-test,
and multivariate modeling will be analyzed using logis-
tic regression. To assess the secondary endpoint, event
rates of death and readmission over time will be summa-
rized using Kaplan—Meier survival curves, and differences in
these curves by the intervention will be analyzed using the
Mantel—Haenszel (log-rank) test. In addition, a Cox propor-
tional hazard model will be ﬁtted for a multivariate analysis.
A p-value below 0.05 will be considered as statistically sig-
niﬁcant and the incidence curves will be considered to be
conﬁrmed as different.
The sample size is based on the assumption that the dis-
ease management program will produce a 30% reduction in
the primary outcome, relative to the control usual care arm,
from the results of previous similar trials for patients with
MI or HF [17,18]. Previous nurse-led, behavioral interven-
tion studies improved scores for depression and anxiety by
a range of 30—40% [17,18]. It was calculated that 156 sub-
jects (78 in each group) will be required to detect a 30%
reduction in events (power of 80%, alpha of 0.05) in the
disease management group, and dropouts and losses were
estimated to be approximately 20% over the duration of the
trial.
m
s
o
mte emergency room/clinic visit Yes/No
givers.
iscussion
-HOMECARE is designed to determine the efﬁcacy of disease
anagement on psychosocial status in HF patients. Depres-
ion is known to obstruct active participation in lifestyle
odiﬁcation and symptom recognition required for taking
ppropriate action in case of worsening symptoms [19].
oreover, depression and anxiety increase risks of mortal-
ty and readmission in patients with HF [8,20]. However,
sychosocial problems are both underestimated and under-
reated in HF patients [21,22]. Nurse-led intervention in
I patients has been reported to reduce psychological dis-
ress [23], whereas no previous studies have evaluated their
ffectiveness in disease management programs for psycho-
ogical disorders in HF. If this study proves their effectiveness
or psychological disorders, they could play an important
ole in improving psychosomatic symptoms, and could even-
ually improve clinical outcomes.
The signiﬁcance of J-HOMECARE conducted in Japan is
lso designed to determine the clinical value of a disease
anagement program across the country and healthcare
ystem. With a rapidly growing aging population in devel-
ped countries, this trial will be able to explain how these
anagement programs can be effective for universal strate-
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Table 4 Components and contents of the home-based disease management program in telephone follow-up.
Components Contents
HF status Assessment of HF-related symptoms, daily weight
Consultation with cardiologist, if needed
General health status Assessment of comorbidity, psychosocial response, and activity of daily living
Consultation with cardiologist or other health professional, if needed
Adherence to medication Assessment of coping with regimen
Assessment of side effects
Support to caregiver’s optimal monitoring for patient’s adherence
Consultation with pharmacist or cardiologist, if needed
Lifestyle modiﬁcation Advice on sodium restriction, ﬂuid restriction, alcohol restriction, and smoking cessation
Consultation with dietician or cardiologist, if needed
Social support needs Assessment of inadequate social support and social isolation
Consultation with social worker, if needed
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CHF, heart failure.
ies for HF, regardless of the differences in ethnicity and
ealthcare systems.
In J-HOMECARE, visiting nurses provide advice and
ounseling regarding coping in the home environment,
ealthcare and social support, and future healthcare needs
or 3 months after discharge. Based on previous studies, the
lements of disease management programs for HF consist of
categories: (1) symptom monitoring; (2) therapeutic mod-
ﬁcation; (3) patient education; and (4) patient adherence
24,25]. In a growing aging population, elderly patients living
ith HF have complex problems, such as living alone, having
n elderly caregiver, or having a mismatch between disabil-
ty in the instrumental activities of daily living (IADL) and life
ircumstances. These problems interfere with their adher-
nce to and maintenance of optimized medical treatment
26]. Therefore, the comprehensive advice and support of
-HOMECARE may play an important role in enhancing the
arious elements of disease management programs.
In conclusion, J-HOMECARE is a multicenter, randomized
rial analyzing the impact of home-based disease man-
gement programs on the psychological status as well as
rognosis and QOL of HF patients in Japan. It is the ﬁrst trial
arried out in Japan to analyze the effect of disease man-
gement on clinical outcomes for Japanese patients and is
H
a
T
Figure 3 Algorithm of home-bxpected to prove its effectiveness in disease management
rrespective of the national health service system. Moreover,
ur intervention has both multidisciplinary and compre-
ensive features including continuing support to manage
atients’ complex problems and enhance their self-care
nd adherence. Results from this trial will help healthcare
roviders to determine the effective components of an HF
anagement program.
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